Table 3 Patients and disease... | American Society of Hematology

Table 3

Patients and disease characteristics associated with MCyR at 1-year and 3-year survival outcomes

Parameter	Category	No.	% 1-year		% 3-year
Parameter	Category	No.	MCyR	P	EFS	P	OS	P
Age, y	< 55	62	64	.01	63	.02	87	.01
Age, y	> 55	61	40	.01	43	.02	81	.01
Splenomegaly	No	114	55	.18	54	.09	85	.09
Splenomegaly	Yes	7	20	.18	0	.09	46	.09
Hemoglobin, g/dL	< 10	15	29	.007	36	.22	59	.08
	10-11	41	43		50		83
	≥ 12	67	68		58		89
WBCs, × 10⁹/L	< 10	56	59	.35	52	.88	87	.48
WBCs, × 10⁹/L	≥ 10	67	50	.35	53	.88	80	.48
Platelets, × 10⁹/L	≤ 450	82	57	.33	55	.38	81	.62
Platelets, × 10⁹/L	> 450	41	47	.33	47	.38	88	.62
Peripheral basophils, %	< 2	57	53	.97	54	.32	86	.92
	2-6	43	54		49		82
	≥ 7	23	57		54		82
Peripheral blasts, %	0	95	57	.1	56	.11	86	.01
	1-2	19	56		48		84
	≥ 3	9	14		15		56
Marrow basophils, %	< 2	55	57	.67	55	.64	89	.23
	2-4	43	48		49		74
	> 4	21	50		45		85
Marrow blasts, %	0	18	75	.05	55	.67	83	.02
	1-2	55	48		49		96
	3-4	31	59		55		71
	≥ 5	15	25		46		60
Clonal evolution	No	94	53	>.999	54	.46	87	.22
Clonal evolution	Yes	28	54	>.999	48	.46	71	.22
CML duration, years	0-3	27	67	.42	41	.56	78	.89
	4-5	41	52		56		83
	≥ 6	55	51		55		87
CHR at the start of second TKI	No	39	60	.42	53	.63	90	.40
CHR at the start of second TKI	Yes	84	51	.42	52	.63	81	.40
Best response to imatinib	Intolerant	8	83	> .999	50	< .001	100	.02
	MCyR	55	75		67		87
	mCyR	22	45		52		81
	No CyR	32	20		30		81
	No data	6	40		40		50
Performance status	0	89	51	.82	56	.02	91	< .001
Performance status	≥ 1	29	54	.82	38	.02	59	< .001
% Ph at the start	≥ 90	35	75	.04	66	.03	91	.41
% Ph at the start	> 90	82	45	.04	45	.03	80	.41
Prior IFN-α	No	53	64	.08	54	.76	79	.85
Prior IFN-α	Yes	70	47	.08	51	.76	87	.85
Mutation status	None	42	50	.08	55	.22	81	.09
	Low IC₅₀	23	65		45		87
	Intermediate IC₅₀	12	25		25		50
	Not done	43	NA		NA		NA

Parameter	Category	No.	% 1-year		% 3-year
Parameter	Category	No.	MCyR	P	EFS	P	OS	P
Age, y	< 55	62	64	.01	63	.02	87	.01
Age, y	> 55	61	40	.01	43	.02	81	.01
Splenomegaly	No	114	55	.18	54	.09	85	.09
Splenomegaly	Yes	7	20	.18	0	.09	46	.09
Hemoglobin, g/dL	< 10	15	29	.007	36	.22	59	.08
	10-11	41	43		50		83
	≥ 12	67	68		58		89
WBCs, × 10⁹/L	< 10	56	59	.35	52	.88	87	.48
WBCs, × 10⁹/L	≥ 10	67	50	.35	53	.88	80	.48
Platelets, × 10⁹/L	≤ 450	82	57	.33	55	.38	81	.62
Platelets, × 10⁹/L	> 450	41	47	.33	47	.38	88	.62
Peripheral basophils, %	< 2	57	53	.97	54	.32	86	.92
	2-6	43	54		49		82
	≥ 7	23	57		54		82
Peripheral blasts, %	0	95	57	.1	56	.11	86	.01
	1-2	19	56		48		84
	≥ 3	9	14		15		56
Marrow basophils, %	< 2	55	57	.67	55	.64	89	.23
	2-4	43	48		49		74
	> 4	21	50		45		85
Marrow blasts, %	0	18	75	.05	55	.67	83	.02
	1-2	55	48		49		96
	3-4	31	59		55		71
	≥ 5	15	25		46		60
Clonal evolution	No	94	53	>.999	54	.46	87	.22
Clonal evolution	Yes	28	54	>.999	48	.46	71	.22
CML duration, years	0-3	27	67	.42	41	.56	78	.89
	4-5	41	52		56		83
	≥ 6	55	51		55		87
CHR at the start of second TKI	No	39	60	.42	53	.63	90	.40
CHR at the start of second TKI	Yes	84	51	.42	52	.63	81	.40
Best response to imatinib	Intolerant	8	83	> .999	50	< .001	100	.02
	MCyR	55	75		67		87
	mCyR	22	45		52		81
	No CyR	32	20		30		81
	No data	6	40		40		50
Performance status	0	89	51	.82	56	.02	91	< .001
Performance status	≥ 1	29	54	.82	38	.02	59	< .001
% Ph at the start	≥ 90	35	75	.04	66	.03	91	.41
% Ph at the start	> 90	82	45	.04	45	.03	80	.41
Prior IFN-α	No	53	64	.08	54	.76	79	.85
Prior IFN-α	Yes	70	47	.08	51	.76	87	.85
Mutation status	None	42	50	.08	55	.22	81	.09
	Low IC₅₀	23	65		45		87
	Intermediate IC₅₀	12	25		25		50
	Not done	43	NA		NA		NA

OS indicates overall survival; WBCs, white blood cells; mCyR, minor cytogenetic response; CyR, cytogenetic response; IFN-α, interferon-α; and NA, not applicable.

View Large

This Feature Is Available To Subscribers Only